共 14 条
[1]
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins[J] . Allen J. Taylor,Lance E. Sullenberger,Hyun J. Lee,Jeannie K. Lee,Karen A. Grace.  Circulation . 2004 (23)
[2]
Effects of aspirin dose onischaemic events and bleeding after percutaneous coronary inter-vention:insights from the PCI-CURE study. Jolly SS,Pogue J,Haladyn K,et al. European Heart Journal . 2009
[3]
Design and rationale of CURRENT-OASIS 7:a randomized,2×2 factorial trial evaluating optimaldosing strategies for clopidogrel and aspirin in patients with STand non-ST-elevation acute coronary syndromes managed with anearly invasive strategy. Mehta SR,Bassand JP,Chrolavicius S,et al. American Heart Journal . 2008
[4]
Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. James SK,Stenestrand U,Lindback J,et al. The New England Journal of Medicine . 2009
[5]
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Taylor AJ,Sullenberger LE,Lee HJ,et al. Circulation . 2004
[6]
COURAGE Trial Research Group.Opti mal medical therapy with or without PCI for stable coronary disease. Boden WE,O‘Rourke RA,Teo KK,et al. The New England Journal of Medicine . 2007
[7]
Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. L.J. Shaw,D.S. Berman,D.J. Maron. Circulation . 2008
[8]
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t. G. Montalescot,G. Sideris,C. Meuleman. Journal of the American College of Cardiology . 2006
[9]
Benefit of a 600-mg loading dose of clopi-dogrel on platelet reactivity and clinical outcomes in patients with non-ST-seg-ment elevation acute coronary syndrome undergoing coronary stenting. Cuisset T,Frere C,Quilici J,et al. Journal of the American College of Cardiology . 2006
[10]
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. Lagerqvist B,James SK,Stenestrand U,et al. The New England Journal of Medicine . 2007